Kuaihua Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announces that its wholly-owned subsidiary, Harbin Kuaihua Pharmaceutical Co., Ltd., has recently received the "Acceptance Notice" from the National Medical Products Administration regarding the registration application for Ambroxol Hydrochloride Oral Solution. The relevant details are as follows:
002737SZSE
Announcement on the Acceptance of Registration Application for Ambroxol Hydrochloride Oral Solution
✨ AI Summary
The announcement informs that Harbin Kuaihua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kuaihua Pharmaceutical Group Co., Ltd., has received acceptance for its registration application for Ambroxol Hydrochloride Oral Solution from the National Medical Products Administration. The product is intended for treating mucus viscosity and difficulty in expectoration caused by acute and chronic bronchitis. The company will actively promote the licensing process and monitor the approval status.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.